Kohei Osawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kohei Osawa has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Kenji Mitsudo
Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa 236-0004, Japan
3 shared publications - Masanari Umemura
Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama-shi, Kanagawa 236-0004, Japan
3 shared publications - Hiroaki Kitajima
Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, Los Angeles, CA 90095-1668, USA
2 shared publications Rina Nakakaji
Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine
2 shared publications- Ryo Tanaka
Department of Neurology, Faculty of Medicine University of Toyama Toyama Japan
2 shared publications Satomi Sugiyama
Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine
2 shared publications
Latest Publications
- Open Access
- 3 February 2026
- Published by Elsevier in The Journal of Physiological Sciences
- Vol. 76 (1) , 100063
Orai1- and STIM1-mediated calcium signaling controls PD-L1 expression and modulates antitumor immunity in oral cancer
- 3 February 2026
- Published by Elsevier in The Journal of Physiological Sciences
- Vol. 76 (1) , 100063
Open AccessOrai1- and STIM1-mediated calcium signaling controls PD-L1 expression and modulates antitumor immunity in oral cancer
- Open Access
- 29 November 2025
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 16 (12) , 449
Comparative Animal Study of Zirconia-Coated Titanium Implants: Effect on Bone Formation and Collagen Fiber Orientation
Tissue responses to zirconia-coated implants treated with molecular precursor method were evaluated. The zirconia film was characterized using scanning electron microscopy (SEM), atomic force microscopy (AFM), energy dispersive X-ray spectroscopy (EDX), X-ray photoelectron spectroscopy (XPS), and X-ray diffraction (XRD). Cylindrical titanium (ZrO2/Ti) specimens were sandblasted, acid-etched, and coated with zirconia using the molecular precursor method. Control specimens were sandblasted and acid-etched only (SLA/Ti). After maxillary first molar extraction, four ZrO2/Ti and four SLA/Ti implants were placed in the alveolar bone of the rats, and tissue responses were observed after 3 weeks. Surface analysis using SEM and AFM showed zirconia was present on ZrO2/Ti surface, with coating not affecting surface morphology compared to SLA/Ti. EDX, XPS, and XRD measurements confirmed the ZrO2 coating on the roughened Ti. The amount of new bone was greater in ZrO2/Ti (77.0 ± 7.2%) than in SLA/Ti (59.7 ± 5.8%) (p = 0.807). Collagen fibers oriented perpendicular to implant surface were observed more frequently in ZrO2/Ti (67.3 ± 9.5%) than in SLA/Ti (18.8 ± 10.01%) (p < 0.001). The area of perpendicular collagen fibers was significantly larger in ZrO2/Ti (53.1 ± 13.4%) than in SLA/Ti (16.8 ± 2.6%) (p = 0.002). Zirconia-coated implants maintained surface morphology and improved bone formation and fiber orientation in the gingiva compared to conventional titanium implants in short-term animal experiments.
- 29 November 2025
- Published by MDPI AG in Journal of Functional Biomaterials
- Vol. 16 (12) , 449
Open AccessComparative Animal Study of Zirconia-Coated Titanium Implants: Effect on Bone Formation and Collagen Fiber Orientation
Tissue responses to zirconia-coated implants treated with molecular precursor method were evaluated. The zirconia film was characterized using scanning electron microscopy (SEM), atomic force microscopy (AFM), energy dispersive X-ray spectroscopy (EDX), X-ray photoelectron spectroscopy (XPS), and X-ray diffraction (XRD). Cylindrical titanium (ZrO2/Ti) specimens were sandblasted, acid-etched, and coated with zirconia using the molecular precursor method. Control specimens were sandblasted and acid-etched only (SLA/Ti). After maxillary first molar extraction, four ZrO2/Ti and four SLA/Ti implants were placed in the alveolar bone of the rats, and tissue responses were observed after 3 weeks. Surface analysis using SEM and AFM showed zirconia was present on ZrO2/Ti surface, with coating not affecting surface morphology compared to SLA/Ti. EDX, XPS, and XRD measurements confirmed the ZrO2 coating on the roughened Ti. The amount of new bone was greater in ZrO2/Ti (77.0 ± 7.2%) than in SLA/Ti (59.7 ± 5.8%) (p = 0.807). Collagen fibers oriented perpendicular to implant surface were observed more frequently in ZrO2/Ti (67.3 ± 9.5%) than in SLA/Ti (18.8 ± 10.01%) (p < 0.001). The area of perpendicular collagen fibers was significantly larger in ZrO2/Ti (53.1 ± 13.4%) than in SLA/Ti (16.8 ± 2.6%) (p = 0.002). Zirconia-coated implants maintained surface morphology and improved bone formation and fiber orientation in the gingiva compared to conventional titanium implants in short-term animal experiments.
- 12 April 2024
- Published by Wiley in Oral Science International
- Vol. 21 (3) , 519-527
Three cases of gingival cancer associated with peri‐implantitis and their management
Background: Dental implant treatment is effective for missing teeth, but it can cause peri‐implantitis. Chronic inflammation may be involved in the development of malignancy. We report three cases of gingival cancer that may have been associated with peri‐implantitis. Case Presentation: All three patients were referred to our department for detailed examination of a mass or ulcerative lesion around implants placed in their family dental clinics. One case of cancer was associated with oral lichen planus and peri‐implantitis. Two cases of cancer were associated with peri‐implantitis. Surgery for gingival cancer was successfully performed. All three pathological diagnoses were well‐differentiated squamous cell carcinoma. Conclusion: Chronic inflammation is a risk factor for malignant tumors, suggesting the importance of its maintenance.
- 12 April 2024
- Published by Wiley in Oral Science International
- Vol. 21 (3) , 519-527
Three cases of gingival cancer associated with peri‐implantitis and their management
Background: Dental implant treatment is effective for missing teeth, but it can cause peri‐implantitis. Chronic inflammation may be involved in the development of malignancy. We report three cases of gingival cancer that may have been associated with peri‐implantitis. Case Presentation: All three patients were referred to our department for detailed examination of a mass or ulcerative lesion around implants placed in their family dental clinics. One case of cancer was associated with oral lichen planus and peri‐implantitis. Two cases of cancer were associated with peri‐implantitis. Surgery for gingival cancer was successfully performed. All three pathological diagnoses were well‐differentiated squamous cell carcinoma. Conclusion: Chronic inflammation is a risk factor for malignant tumors, suggesting the importance of its maintenance.
- Open Access
- 20 May 2021
- Published by Japanese Society of Oral and Maxillofacial Surgeons in Japanese Journal of Oral and Maxillofacial Surgery
- Vol. 67 (5) , 258-264
A clinical study of sialolithiasis in children
Sialolithiasis is rare in children. We thus examined the 111 cases of sialolithiasis patients younger than 16 years old who were treated in the Department of Oral and Maxillofacial Surgery / Orthodontics, Yokohama City University Hospital between January 2007 and August 2018. The patients included 61 males and 50 females. Their ages ranged from 4 to 15 years. 110 patients had sialoliths in the submandibular gland and one patient in the parotid gland. Of the 111 patients, 78 complained of swelling on their first visit. There was one patient with no symptoms. Almost all patients (109) underwent a CT scan and two patients underwent occlusal radiography. The majority of the patients (84) had only one sialolith, and most of the sialolith were less than 5 mm in diameter. The submandibular sialoliths were frequently seen in the transitional region and the gland duct. Of the 111 patients, 60 underwent intraoral removal, 33 underwent endoscopic removal with sialendoscope, and 9 underwent removal using both approaches. This study clarified the characteristics and treatment of pediatric sialolithiasis patients.
- 20 May 2021
- Published by Japanese Society of Oral and Maxillofacial Surgeons in Japanese Journal of Oral and Maxillofacial Surgery
- Vol. 67 (5) , 258-264
Open AccessA clinical study of sialolithiasis in children
Sialolithiasis is rare in children. We thus examined the 111 cases of sialolithiasis patients younger than 16 years old who were treated in the Department of Oral and Maxillofacial Surgery / Orthodontics, Yokohama City University Hospital between January 2007 and August 2018. The patients included 61 males and 50 females. Their ages ranged from 4 to 15 years. 110 patients had sialoliths in the submandibular gland and one patient in the parotid gland. Of the 111 patients, 78 complained of swelling on their first visit. There was one patient with no symptoms. Almost all patients (109) underwent a CT scan and two patients underwent occlusal radiography. The majority of the patients (84) had only one sialolith, and most of the sialolith were less than 5 mm in diameter. The submandibular sialoliths were frequently seen in the transitional region and the gland duct. Of the 111 patients, 60 underwent intraoral removal, 33 underwent endoscopic removal with sialendoscope, and 9 underwent removal using both approaches. This study clarified the characteristics and treatment of pediatric sialolithiasis patients.
- Open Access
- 1 January 2020
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 93, 1-010
EP4 receptor regulates cell migration and apoptosis in oral cancer
【Background】The EP4 prostanoid receptors are one of the four receptor subtypes for Prostaglandin E2 (PGE2). EP4 plays an important role in cancer progression. Its inhibition is a potential strategy for cancer therapy. However, little information is available regarding cell apoptosis and cellular signaling pathway of EP4 in oral cancer. In current study, we examined that EP4 signal regulates cell apoptosis and chemotherapeutic resistance in oral cancer.【Material and Method】Human-derived tongue squamous cell carcinoma cell lines, HSC-3 was used. Western blot analysis was performed to evaluate the proteins, which is associated with cell migration and apoptosis in cancer (E-cadherin, N-cadherin, claudin-1, ZEB1, ZO-1, galectin-3, fibronectin, Bcl-2, Bax). Cell apoptosis was evaluated by flowcytometry. 【Result】EP4 agonist (ONO-AE1-437) increased expression of galectin-3 in HSC-3 cells (p<0.001). EP4 agonist also increased claudin-1 expression. The other proteins were not changed by the EP4 agonist stimulation. Furthermore, EP4 agonist inhibited cisplatin-induced early apoptosis of oral cancer cells and decreased late apoptosis and necrosis.【Conclusion】Activation of EP4 signal may increase the expression of galectin-3 and promote cell apoptosis, resulting in a chemotherapeutic resistance of oral cancer.
- 1 January 2020
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 93, 1-010
Open AccessEP4 receptor regulates cell migration and apoptosis in oral cancer
【Background】The EP4 prostanoid receptors are one of the four receptor subtypes for Prostaglandin E2 (PGE2). EP4 plays an important role in cancer progression. Its inhibition is a potential strategy for cancer therapy. However, little information is available regarding cell apoptosis and cellular signaling pathway of EP4 in oral cancer. In current study, we examined that EP4 signal regulates cell apoptosis and chemotherapeutic resistance in oral cancer.【Material and Method】Human-derived tongue squamous cell carcinoma cell lines, HSC-3 was used. Western blot analysis was performed to evaluate the proteins, which is associated with cell migration and apoptosis in cancer (E-cadherin, N-cadherin, claudin-1, ZEB1, ZO-1, galectin-3, fibronectin, Bcl-2, Bax). Cell apoptosis was evaluated by flowcytometry. 【Result】EP4 agonist (ONO-AE1-437) increased expression of galectin-3 in HSC-3 cells (p<0.001). EP4 agonist also increased claudin-1 expression. The other proteins were not changed by the EP4 agonist stimulation. Furthermore, EP4 agonist inhibited cisplatin-induced early apoptosis of oral cancer cells and decreased late apoptosis and necrosis.【Conclusion】Activation of EP4 signal may increase the expression of galectin-3 and promote cell apoptosis, resulting in a chemotherapeutic resistance of oral cancer.
- Open Access
- 1 January 2020
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 93, 2-226
Simultaneous hyperthermia-chemotherapy effect by arterial injection of Fe(Salen) for femur tumor
Introduction: We previously identified a novel magnetic organic compound, N,N'-bis(salicylidene)ethylenediamine iron [Fe(Salen)], as an anti-cancer agent with intrinsic magnetism. Fe(Salen) can generate heat, i.e. hyperthermia upon exposure to alternating magnetic field (AMF) like an induction cooker. The purpose of the study was to evaluate the antitumor effect of intra-arterial (i.a.) selective injection of Fe(Salen) by catheter with/without the AMF-induced hyperthermia or intra-venous (i.v.) injection. We also investigated the anticancer mechanism of Fe(Salen) and the therapeutic dose through toxicity study. Methods: Rabbit squamous cell carcinoma (VX2) cells were purchased from ATCC. Rabbit tumor model implanted with VX2 cells in the right femur was used. Western blotting, mitochondrial membrane potential and Immunocytochemistry for STAT3 subcellular distribution were performed. Results: Intra-arterial selective injection of Fe(Salen) by catheter showed the greater antitumor effect than that of i.v. injection. The combination of intra-arterial injection of Fe(Salen) and AMF exposure showed the greater effect than either Fe(Salen) or methotrexate (MTX) without AMF. Fe(Salen) showed antitumor effect via MEK/ERK/STAT3 signaling pathways. Conclusion: This is the first report that the effectiveness of Fe(Salen) was evaluated in the point of administration route. These results indicate the effective arterial injection of Fe(Salen) by catheter and the development of new strategy of simultaneous hyperthermia-chemotherapy.
- 1 January 2020
- Published by Japanese Pharmacological Society in Proceedings for Annual Meeting of The Japanese Pharmacological Society
- Vol. 93, 2-226
Open AccessSimultaneous hyperthermia-chemotherapy effect by arterial injection of Fe(Salen) for femur tumor
Introduction: We previously identified a novel magnetic organic compound, N,N'-bis(salicylidene)ethylenediamine iron [Fe(Salen)], as an anti-cancer agent with intrinsic magnetism. Fe(Salen) can generate heat, i.e. hyperthermia upon exposure to alternating magnetic field (AMF) like an induction cooker. The purpose of the study was to evaluate the antitumor effect of intra-arterial (i.a.) selective injection of Fe(Salen) by catheter with/without the AMF-induced hyperthermia or intra-venous (i.v.) injection. We also investigated the anticancer mechanism of Fe(Salen) and the therapeutic dose through toxicity study. Methods: Rabbit squamous cell carcinoma (VX2) cells were purchased from ATCC. Rabbit tumor model implanted with VX2 cells in the right femur was used. Western blotting, mitochondrial membrane potential and Immunocytochemistry for STAT3 subcellular distribution were performed. Results: Intra-arterial selective injection of Fe(Salen) by catheter showed the greater antitumor effect than that of i.v. injection. The combination of intra-arterial injection of Fe(Salen) and AMF exposure showed the greater effect than either Fe(Salen) or methotrexate (MTX) without AMF. Fe(Salen) showed antitumor effect via MEK/ERK/STAT3 signaling pathways. Conclusion: This is the first report that the effectiveness of Fe(Salen) was evaluated in the point of administration route. These results indicate the effective arterial injection of Fe(Salen) by catheter and the development of new strategy of simultaneous hyperthermia-chemotherapy.
- 1 May 2018
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
- Vol. 30 (3) , 278-280
Peripheral osteoma arising from the lateral surface of the mandibular ramus
- 1 May 2018
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
- Vol. 30 (3) , 278-280
Peripheral osteoma arising from the lateral surface of the mandibular ramus